Discovery founded through merger, combined biospecimen repository tops 10m

By Maggie Lynch

- Last updated on GMT

(Image: Getty/metamorworks)
(Image: Getty/metamorworks)
Four companies have merged under the name Discovery Life Sciences, joining forces to offer biospecimen analysis and procurement services.

Conversant Bio, Folio Bio, Legacy Discovery Life Sciences, and Phylogeny make up Discovery Life Sciences, a biospecimen analysis and procurement group for the pharmaceutical, biotechnology, and diagnostics industries.

The new company will leverage its respective consultative services along with a repository of more than 10m research-quality biospecimens—all available and processed for analysis.

Glenn Bilawsky CEO of Discovery told us, “We believe that our knowledge and innovative approach will accelerate the time from discovery through validation to commercialization of novel biomarkers, drug candidates, medical devices, and diagnostics.”

The company will focus on oncology, cardiology, neurology, as well as infectious, inflammatory, and autoimmune diseases.

Per the merger, the company’s newly combined catalog includes normal, suspect, and disease-state specimens. Including specimens of rare diseases and racially and ethnically diverse exemplars.

Discovery obtains these biosamples through its global, integrated network of more than 165 clinical sources, in 25 countries on six continents – Discovery Partners. Bilawsky said that these partners are “the route to hundreds of thousands of patients.”​ The company collaborates with a network of hospitals, medical centers, blood banks, clinical laboratories, and community-based medical practices.

The company stated that it can study specimens on all research and diagnostic platforms as an ISO 9001-certified company with CLIA-certified labs, IRB and Ethics Committee compliance, and all required EU approvals and certifications.

The merger was facilitated by Water Street Healthcare Partners, which also invested in the company.

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Related suppliers

Follow us

Products

View more

Webinars